Mesenchymal stromal cell therapy for chronic lung diseases: experimental and clinical evidence

References

• Labaki WW, Han MK. Chronic respiratory diseases: a global view. Lancet Respir Med. 2020;8(6):531–533.
   PubMed Web of Science ®Google Scholar
• World Health Organization. The top 10 causes of death [Internet] [cited 2022Jul11]. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
   Google Scholar
• Weiss DJ, Bates JHT, Gilbert T, et al. Stem cells and cell therapies in lung biology and diseases: conference report. Ann Am Thorac Soc. 2013;10(5):S25–44. DOI:10.1513/AnnalsATS.201304-089AW
   PubMedGoogle Scholar
• Cho SJ, Stout-Delgado HW. Aging and lung disease. Annu Rev Physiol. 2020;82(1):433–459.
   PubMedGoogle Scholar
• Weiss DJ. Concise review: current status of stem cells and regenerative medicine in lung biology and diseases. Stem Cells. 2014;32(1):16–25.
   PubMedGoogle Scholar
• Kotton DN. Next-generation regeneration: the hope and hype of lung stem cell research. Am J Respir Crit Care Med. 2012;185(12):1255–1260.
   PubMedGoogle Scholar
• Cruz FF, Rocco PRM. The potential of mesenchymal stem cell therapy for chronic lung disease. Expert Rev Respir Med. 2020;14(1):31–39.
   PubMedGoogle Scholar
• Afanasyev B, Elstner E, Zander AAJ. Friedenstein, founder of the mesenchymal stem cell concept. Cell Ther Transplant. 2009;1:35–38.
   Google Scholar
• Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8:315–317.
   PubMed Web of Science ®Google Scholar
• Ding D-C, Shyu W-C, Lin S-Z. Mesenchymal stem cells. Cell Transplant. 2011;20(1):5–14.
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: the international society for cellular therapy position statement. Cytotherapy. 2005;7(5):393–395. DOI:10.1080/14653240500319234
   PubMed Web of Science ®Google Scholar
• Dennis JE, Cohen N, Goldberg VM, et al. Targeted delivery of progenitor cells for cartilage repair. J Orthop Res. 2004;22(4):735–741. DOI:10.1016/j.orthres.2003.12.002
   PubMedGoogle Scholar
• Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012;12(5):383–396.
   PubMed Web of Science ®Google Scholar
• Viswanathan S, Shi Y, Galipeau J, et al. Mesenchymal stem versus stromal cells: international Society for Cell & Gene Therapy (ISCT®) mesenchymal stromal cell committee position statement on nomenclature. Cytotherapy. 2019;21(10):1019–1024. DOI:10.1016/j.jcyt.2019.08.002
   PubMed Web of Science ®Google Scholar
• Han Y, Li X, Zhang Y, et al. Mesenchymal stem cells for regenerative medicine. Cells. 2019;8(8):886. DOI:10.3390/cells8080886
   PubMed Web of Science ®Google Scholar
• Caplan AI. Mesenchymal stem cells: the past, the present, the future. Cartilage. 2010;1(1):6–9.
   PubMedGoogle Scholar
• Prockop DJ, Youn Oh J. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther. 2012;20(1):14–20.
   PubMed Web of Science ®Google Scholar
• Harrell C, Fellabaum C, Jovicic N, et al. Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome. Cells. 2019;8(5):467. DOI:10.3390/cells8050467
   PubMed Web of Science ®Google Scholar
• Li N, Hua J. Interactions between mesenchymal stem cells and the immune system. Cell Mol Life Sci. 2017;74(13):2345–2360.
   PubMed Web of Science ®Google Scholar
• Abreu SC, Lopes-Pacheco M, Weiss DJ, et al. Mesenchymal stromal cell-derived extracellular vesicles in lung diseases: current status and perspectives. Front Cell Dev Biol. 2021;9:600711.
   PubMedGoogle Scholar
• Zhuang W-Z, Lin Y-H, L-J S, et al. Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications. J Biomed Sci. 2021;28(1):28. DOI:10.1186/s12929-021-00725-7
   PubMed Web of Science ®Google Scholar
• Liu X, Chen Z. The pathophysiological role of mitochondrial oxidative stress in lung diseases. J Transl Med. 2017;15(1):207.
   PubMedGoogle Scholar
• Caldeira D de AF, Weiss DJ, Rocco PRM, et al. Mitochondria in focus: from function to therapeutic strategies in chronic lung diseases. Front Immunol. 2021;12:782074.
   PubMedGoogle Scholar
• Cofano F, Boido M, Monticelli M, et al. Mesenchymal stem cells for spinal cord injury: current options, limitations, and future of cell therapy. Int J Mol Sci. 2019;20(11):2698. DOI:10.3390/ijms20112698
   PubMed Web of Science ®Google Scholar
• Iyer SS, Rojas M. Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Expert Opin Biol Ther. 2008;8(5):569–581.
   PubMed Web of Science ®Google Scholar
• El Agha E, Kramann R, Schneider RK, et al. Mesenchymal stem cells in fibrotic disease. Cell Stem Cell. 2017;21(2):166–177. DOI:10.1016/j.stem.2017.07.011
   PubMed Web of Science ®Google Scholar
• Wei LJ, Wei L, Han Z, et al. Mesenchymal stromal cells-derived exosomes alleviate ischemia/reperfusion injury in mouse lung by transporting anti-apoptotic miR-21-5p. Eur J Pharmacol. 2019;852:68–76.
   PubMedGoogle Scholar
• Silva-Carvalho AÉ, Cardoso MH, Alencar-Silva T, et al. Dissecting the relationship between antimicrobial peptides and mesenchymal stem cells. Pharmacol Ther. 2022;233:108021.
   PubMedGoogle Scholar
• Wang X, Zhao S, Lai J, et al. Anti-inflammatory, antioxidant, and antifibrotic effects of gingival-derived MSCs on bleomycin-induced pulmonary fibrosis in mice. Int J Mol Sci. 2021;23(1):99. DOI:10.3390/ijms23010099
   PubMed Web of Science ®Google Scholar
• Kim S-Y, Lee J-H, Kim HJ, et al. Mesenchymal stem cell-conditioned media recovers lung fibroblasts from cigarette smoke-induced damage. Am J Physiol Lung Cell Mol Physiol. 2012;302(9):L891–908. DOI:10.1152/ajplung.00288.2011
   PubMed Web of Science ®Google Scholar
• J-W L, Wu X. Mesenchymal stem cells ameliorate LPS-induced acute lung injury through KGF promoting alveolar fluid clearance of alveolar type II cells. Eur Rev Med Pharmacol Sci. 2015;19(13):2368–2378.
   PubMedGoogle Scholar
• Qin H, Zhao A. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. Protein Cell. 2020;11(10):707–722.
   PubMed Web of Science ®Google Scholar
• Sanabria-de la Torre R, Quiñones-Vico MI, Fernández-González A, et al. Alloreactive immune response associated to human mesenchymal stromal cells treatment: a systematic review. J Clin Med. 2021;10(13):2991. DOI:10.3390/jcm10132991
   PubMedGoogle Scholar
• Mao AS, Shin J-W, Mooney DJ. Effects of substrate stiffness and cell-cell contact on mesenchymal stem cell differentiation. Biomaterials. 2016;98:184–191.
   PubMedGoogle Scholar
• Reddel HK, Bacharier LB, Bateman ED, et al. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. Eur Respir J. 2022;59(1):2102730. DOI:10.1183/13993003.02730-2021
   PubMed Web of Science ®Google Scholar
• Calhoun WJ, Chupp GL. The new era of add-on asthma treatments: where do we stand? Allergy, Asthma Clin Immunol. 2022;18(1):42.
   PubMedGoogle Scholar
• Kitoko JZ, de Castro LL, Nascimento AP, et al. Therapeutic administration of bone marrow-derived mesenchymal stromal cells reduces airway inflammation without up-regulating Tregs in experimental asthma. Clin Exp Allergy. 2018;48(2):205–216. DOI:10.1111/cea.13048
   PubMed Web of Science ®Google Scholar
• Keyhanmanesh R, Rahbarghazi R, Ahmadi M. Systemic transplantation of mesenchymal stem cells modulates endothelial cell adhesion molecules induced by ovalbumin in rat model of asthma. Inflammation. 2018;41(6):2236–2245.
   PubMedGoogle Scholar
• de Castro LL, Xisto DG, Kitoko JZ, et al. Human adipose tissue mesenchymal stromal cells and their extracellular vesicles act differentially on lung mechanics and inflammation in experimental allergic asthma. Stem Cell Res Ther. 2017;8(1):151. DOI:10.1186/s13287-017-0600-8
   PubMed Web of Science ®Google Scholar
• Castro LL, Kitoko JZ, Xisto DG, et al. Multiple doses of adipose tissue-derived mesenchymal stromal cells induce immunosuppression in experimental asthma. Stem Cells Transl Med. 2020;9(2):250–260. DOI:10.1002/sctm.19-0120
   PubMedGoogle Scholar
• Abreu SC, Lopes-Pacheco M, da Silva AL, et al. Eicosapentaenoic acid enhances the effects of mesenchymal stromal cell therapy in experimental allergic asthma. Front Immunol. 2018;9:1147.
   PubMed Web of Science ®Google Scholar
• Abreu SC, Xisto DG, Oliveira TB, et al. Serum from asthmatic mice potentiates the therapeutic effects of mesenchymal stromal cells in experimental allergic asthma. Stem Cells Transl Med. 2019;8(3):301–312. DOI:10.1002/sctm.18-0056
   PubMedGoogle Scholar
• Shin JW, Ryu S, Ham J, et al. Mesenchymal stem cells suppress severe asthma by directly regulating Th2 Cells and Type 2 innate lymphoid cells. Mol Cells. 2021;44(8):580–590. DOI:10.14348/molcells.2021.0101
   PubMedGoogle Scholar
• Kim RL, Bang J-Y, Kim J, et al. Mesenchymal stem cells exert their anti-asthmatic effects through macrophage modulation in a murine chronic asthma model. Sci Rep. 2022;12(1):9811. DOI:10.1038/s41598-022-14027-x
   PubMedGoogle Scholar
• Lathrop MJ, Brooks EM, Bonenfant NR, et al. Mesenchymal stromal cells mediate Aspergillus hyphal extract-induced allergic airway inflammation by inhibition of the Th17 signaling pathway. Stem Cells Transl Med. 2014;3(2):194–205. DOI:10.5966/sctm.2013-0061
   PubMedGoogle Scholar
• Cruz FF, Rocco PRM, Weiss DJ. hMscs as an alternative therapeutic option for asthma with neutrophil mediated inflammation. Exp Mol Med. 2018;50(6):1–2.
   PubMedGoogle Scholar
• Cruz FF, Borg ZD, Goodwin M, et al. Systemic administration of human bone marrow-derived mesenchymal stromal cell extracellular vesicles ameliorates Aspergillus hyphal extract-induced allergic airway inflammation in immunocompetent mice. Stem Cells Transl Med. 2015;4(11):1302–1316. DOI:10.5966/sctm.2014-0280
   PubMed Web of Science ®Google Scholar
• Cruz FF, Borg ZD, Goodwin M, et al. Freshly thawed and continuously cultured human bone marrow-derived mesenchymal stromal cells comparably ameliorate allergic airways inflammation in immunocompetent mice. Stem Cells Transl Med. 2015;4(6):615–624. DOI:10.5966/sctm.2014-0268
   PubMedGoogle Scholar
• Cruz FF, Borg ZD, Goodwin M, et al. Cd11b+ and Sca-1+ cells exert the main beneficial effects of systemically administered bone marrow-derived mononuclear cells in a murine model of mixed Th2/Th17 allergic airway inflammation. Stem Cells Transl Med. 2016;5(4):488–499. DOI:10.5966/sctm.2015-0141
   PubMedGoogle Scholar
• Abreu SC, Antunes MA, Mendonça L, et al. Effects of bone marrow mononuclear cells from healthy or ovalbumin-induced lung inflammation donors on recipient allergic asthma mice. Stem Cell Res Ther. 2014;5(5):108. DOI:10.1186/scrt496
   PubMedGoogle Scholar
• Ionescu LI, Alphonse RS, Arizmendi N, et al. Airway delivery of soluble factors from plastic-adherent bone marrow cells prevents murine asthma. Am J Respir Cell Mol Biol. 2012;46(2):207–216. DOI:10.1165/rcmb.2010-0391OC
   PubMed Web of Science ®Google Scholar
• Du Y, Zhuansun Y, Chen R, et al. Mesenchymal stem cell exosomes promote immunosuppression of regulatory T cells in asthma. Exp Cell Res. 2018;363(1):114–120. DOI:10.1016/j.yexcr.2017.12.021
   PubMed Web of Science ®Google Scholar
• Yang W, Li F, Li C, et al. Focus on early COPD: definition and early lung development. Int J Chron Obstruct Pulmon Dis. 2021;16:3217–3228.
   PubMed Web of Science ®Google Scholar
• Cruz FF, Antunes MA, Abreu SC, et al. Protective effects of bone marrow mononuclear cell therapy on lung and heart in an elastase-induced emphysema model. Respir Physiol Neurobiol. 2012;182(1):26–36. DOI:10.1016/j.resp.2012.01.002
   PubMed Web of Science ®Google Scholar
• Machado MN, Mazzoli-Rocha F, Casquilho NV, et al. Bone marrow-derived mononuclear cell therapy in papain-induced experimental pulmonary emphysema. Front Physiol. 2018;9:121.
   PubMed Web of Science ®Google Scholar
• Kim Y-S, Kim J-Y, Shin D-M, et al. Tracking intravenous adipose-derived mesenchymal stem cells in a model of elastase-induced emphysema. Tuberc Respir Dis. 2014;77(3):116. DOI:10.4046/trd.2014.77.3.116
   PubMedGoogle Scholar
• Hong Y, Kim Y-S, Hong S-H, et al. Therapeutic effects of adipose-derived stem cells pretreated with pioglitazone in an emphysema mouse model. Exp Mol Med. 2016;48(10):e266. DOI:10.1038/emm.2016.93
   PubMed Web of Science ®Google Scholar
• Ingenito EP, Tsai L, Murthy S, et al. Autologous lung-derived mesenchymal stem cell transplantation in experimental emphysema. Cell Transplant. 2012;21(1):175–189. DOI:10.3727/096368910X550233
   PubMedGoogle Scholar
• Antunes MA, Abreu SC, Cruz FF, et al. Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema. Respir Res. 2014;15(1):118. DOI:10.1186/s12931-014-0118-x
   PubMed Web of Science ®Google Scholar
• Furuya N, Takenaga M, Ohta Y, et al. Cell therapy with adipose tissue-derived stem/stromal cells for elastase-induced pulmonary emphysema in rats. Regener Med. 2012;7(4):503–512. DOI:10.2217/rme.12.25
   PubMedGoogle Scholar
• Zhen G. Mesenchymal stem cells transplantation protects against rat pulmonary emphysema. Front Biosci. 2008;13(13):3415–3422.
   PubMedGoogle Scholar
• Schweitzer KS, Johnstone BH, Garrison J, et al. Adipose stem cell treatment in mice attenuates lung and systemic injury induced by cigarette smoking. Am J Respir Crit Care Med. 2011;183(2):215–225. DOI:10.1164/rccm.201001-0126OC
   PubMed Web of Science ®Google Scholar
• Guan X-J, Song L, Han F-F, et al. Mesenchymal stem cells protect cigarette smoke-damaged lung and pulmonary function partly via VEGF-VEGF receptors. J Cell Biochem. 2013;114(2):323–335. DOI:10.1002/jcb.24377
   PubMed Web of Science ®Google Scholar
• Gu W, Song L, X-M L, et al. Mesenchymal stem cells alleviate airway inflammation and emphysema in COPD through down-regulation of cyclooxygenase-2 via p38 and ERK MAPK pathways. Sci Rep. 2015;5(1):8733. DOI:10.1038/srep08733
   PubMedGoogle Scholar
• Huh JW, Kim S-Y, Lee JH, et al. Bone marrow cells repair cigarette smoke-induced emphysema in rats. Am J Physiol Lung Cell Mol Physiol. 2011;301(3):L255–266. DOI:10.1152/ajplung.00253.2010
   PubMed Web of Science ®Google Scholar
• Kennelly H, Mahon BP, English K. Human mesenchymal stromal cells exert HGF dependent cytoprotective effects in a human relevant pre-clinical model of COPD. Sci Rep. 2016;6(1):38207.
   PubMedGoogle Scholar
• Kim Y-S, Kim J-Y, Cho R, et al. Adipose stem cell-derived nanovesicles inhibit emphysema primarily via an FGF2-dependent pathway. Exp Mol Med. 2017;49(1):e284. DOI:10.1038/emm.2016.127
   PubMed Web of Science ®Google Scholar
• Ridzuan N, Zakaria N, Widera D, et al. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles ameliorate airway inflammation in a rat model of chronic obstructive pulmonary disease (COPD). Stem Cell Res Ther. 2021;12(1):54. DOI:10.1186/s13287-020-02088-6
   PubMed Web of Science ®Google Scholar
• Antunes MA, Braga CL, Oliveira TB, et al. Mesenchymal stromal cells from emphysematous donors and their extracellular vesicles are unable to reverse cardiorespiratory dysfunction in experimental severe emphysema. Front Cell Dev Biol. 2021;9:661385.
   PubMedGoogle Scholar
• Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389(10082):1941–1952.
   PubMed Web of Science ®Google Scholar
• Glass DS, Grossfeld D, Renna HA, et al. Idiopathic pulmonary fibrosis: molecular mechanisms and potential treatment approaches. Respir Investig. 2020;58(5):320–335. DOI:10.1016/j.resinv.2020.04.002
   PubMedGoogle Scholar
• Srour N, Thébaud B. Mesenchymal stromal cells in animal bleomycin pulmonary fibrosis models: a systematic review. Stem Cells Transl Med. 2015;4(12):1500–1510.
   PubMed Web of Science ®Google Scholar
• Llontop P, Lopez-Fernandez D, Clavo B, et al. Airway transplantation of adipose stem cells protects against bleomycin-induced pulmonary fibrosis. J Investig Med. 2018;66(4):739–746. DOI:10.1136/jim-2017-000494
   PubMedGoogle Scholar
• Lee SH, Lee EJ, Lee SY, et al. The effect of adipose stem cell therapy on pulmonary fibrosis induced by repetitive intratracheal bleomycin in mice. Exp Lung Res. 2014;40(3):117–125. DOI:10.3109/01902148.2014.881930
   PubMed Web of Science ®Google Scholar
• Garcia O, Carraro G, Turcatel G, et al. Amniotic fluid stem cells inhibit the progression of bleomycin-induced pulmonary fibrosis via CCL2 modulation in bronchoalveolar lavage. PLoS ONE. 2013;8:e71679.
   PubMedGoogle Scholar
• Huang K, Kang X, Wang X, et al. Conversion of bone marrow mesenchymal stem cells into type II alveolar epithelial cells reduces pulmonary fibrosis by decreasing oxidative stress in rats. Mol Med Rep. 2015;11(3):1685–1692. DOI:10.3892/mmr.2014.2981
   PubMed Web of Science ®Google Scholar
• Moodley Y, Atienza D, Manuelpillai U, et al. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Am J Pathol. 2009;175(1):303–313. DOI:10.2353/ajpath.2009.080629
   PubMed Web of Science ®Google Scholar
• Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A. 2003;100(14):8407–8411. DOI:10.1073/pnas.1432929100
   PubMed Web of Science ®Google Scholar
• Moodley Y, Vaghjiani V, Chan J, et al. Anti-inflammatory effects of adult stem cells in sustained lung injury: a comparative study. PLoS ONE. 2013;8(8):e69299. DOI:10.1371/journal.pone.0069299
   PubMed Web of Science ®Google Scholar
• Shen Q, Chen B, Xiao Z, et al. Paracrine factors from mesenchymal stem cells attenuate epithelial injury and lung fibrosis. Mol Med Rep. 2015;11(4):2831–2837. DOI:10.3892/mmr.2014.3092
   PubMed Web of Science ®Google Scholar
• Filidou E, Kandilogiannakis L, Tarapatzi G, et al. Conditioned medium from a human adipose-derived stem cell line ameliorates inflammation and fibrosis in a lung experimental model of idiopathic pulmonary fibrosis. Life Sci. 2021;287:120123.
   PubMedGoogle Scholar
• Shao L, Zhang Y, Shi W, et al. Mesenchymal stromal cells can repair radiation-induced pulmonary fibrosis via a DKK-1-mediated Wnt/β-catenin pathway. Cell Tissue Res. 2021;384(1):87–97. DOI:10.1007/s00441-020-03325-3
   PubMedGoogle Scholar
• Shentu T-P, Huang T-S, Cernelc-Kohan M, et al. Thy-1 dependent uptake of mesenchymal stem cell-derived extracellular vesicles blocks myofibroblastic differentiation. Sci Rep. 2017;7(1):18052. DOI:10.1038/s41598-017-18288-9
   PubMedGoogle Scholar
• Tan JL, Lau SN, Leaw B, et al. Amnion epithelial cell-derived exosomes restrict lung injury and enhance endogenous lung repair. Stem Cells Transl Med. 2018;7(2):180–196. DOI:10.1002/sctm.17-0185
   PubMed Web of Science ®Google Scholar
• Mansouri N, Willis GR, Fernandez-Gonzalez A, et al. Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through modulation of monocyte phenotypes. JCI Insight. 2019;4(21):e128060. DOI:10.1172/jci.insight.128060
   PubMed Web of Science ®Google Scholar
• Sun L, Zhu M, Feng W, et al. Exosomal miRNA Let-7 from menstrual blood-derived endometrial stem cells alleviates pulmonary fibrosis through regulating mitochondrial DNA damage. Oxid Med Cell Longev. 2019;2019:1–17.
   Web of Science ®Google Scholar
• Wan X, Chen S, Fang Y, et al. Mesenchymal stem cell‐derived extracellular vesicles suppress the fibroblast proliferation by downregulating FZD6 expression in fibroblasts via micrRna‐29b‐3p in idiopathic pulmonary fibrosis. J Cell Physiol. 2020;235(11):8613–8625. DOI:10.1002/jcp.29706
   PubMedGoogle Scholar
• Lei X, He N, Zhu L, et al. Mesenchymal stem cell-derived extracellular vesicles attenuate radiation-induced lung injury via miRNA-214-3p. Antioxid Redox Signal. 2021;35(11):849–862. DOI:10.1089/ars.2019.7965
   PubMed Web of Science ®Google Scholar
• Vazquez ZGS, Klinger JR. Guidelines for the treatment of pulmonary arterial hypertension. Lung. 2020;198(4):581–596.
   PubMedGoogle Scholar
• Lan N, Massam B, Kulkarni S, et al. Pulmonary arterial hypertension: pathophysiology and treatment. Diseases. 2018;6(2):38. DOI:10.3390/diseases6020038
   PubMedGoogle Scholar
• Baber SR, Deng W, Master RG, et al. Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2007;292(2):H1120–1128. DOI:10.1152/ajpheart.00173.2006
   PubMed Web of Science ®Google Scholar
• de Mendonça L, Felix NS, Blanco NG, et al. Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension. Stem Cell Res Ther. 2017;8(1):220. DOI:10.1186/s13287-017-0669-0
   PubMedGoogle Scholar
• Umar S, de Visser YP, Steendijk P, et al. Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2009;297(5):H1606–1616. DOI:10.1152/ajpheart.00590.2009
   PubMed Web of Science ®Google Scholar
• Shao F, Liu R, Tan X, et al. MSC Transplantation attenuates inflammation, prevents endothelial damage and enhances the angiogenic potency of endogenous MSCs in a model of pulmonary arterial hypertension. J Inflamm Res. 2022;15:2087–2101.
   PubMed Web of Science ®Google Scholar
• Cheng G, Wang X, Li Y, et al. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling. Stem Cell Res Ther. 2017;8(1):34. DOI:10.1186/s13287-017-0480-y
   PubMedGoogle Scholar
• Liu J, Han Z, Han Z, et al. Mesenchymal stem cell-conditioned media suppresses inflammation-associated overproliferation of pulmonary artery smooth muscle cells in a rat model of pulmonary hypertension. Exp Ther Med. 2016;11(2):467–475. DOI:10.3892/etm.2015.2953
   PubMedGoogle Scholar
• Rathinasabapathy A, Bruce E, Espejo A, et al. Therapeutic potential of adipose stem cell-derived conditioned medium against pulmonary hypertension and lung fibrosis: adipose stem cells attenuate pulmonary hypertension/fibrosis. Br J Pharmacol. 2016;173(19):2859–2879. DOI:10.1111/bph.13562
   PubMedGoogle Scholar
• Lee C, Mitsialis SA, Aslam M, et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation. 2012;126(22):2601–2611. DOI:10.1161/CIRCULATIONAHA.112.114173
   PubMed Web of Science ®Google Scholar
• Chen J, An R, Liu Z, et al. Therapeutic effects of mesenchymal stem cell-derived microvesicles on pulmonary arterial hypertension in rats. Acta Pharmacol Sin. 2014;35(9):1121–1128. DOI:10.1038/aps.2014.61
   PubMed Web of Science ®Google Scholar
• Aliotta JM, Pereira M, Wen S, et al. Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice. Cardiovasc Res. 2016;110(3):319–330. DOI:10.1093/cvr/cvw054
   PubMed Web of Science ®Google Scholar
• Liu Z, Liu J, Xiao M, et al. Mesenchymal stem cell–derived microvesicles alleviate pulmonary arterial hypertension by regulating renin-angiotensin system. J Am Soc Hypertens. 2018;12(6):470–478. DOI:10.1016/j.jash.2018.02.006
   PubMed Web of Science ®Google Scholar
• Jiao J, Li L, Yao W, et al. Influence of silica exposure for lung silicosis rat. Dis Markers. 2021;2021:1–9.
   Google Scholar
• Barnes H, Goh NSL, Leong TL, et al. Silica‐associated lung disease: an old‐world exposure in modern industries. Respirology. 2019;24(12):1165–1175. DOI:10.1111/resp.13695
   PubMed Web of Science ®Google Scholar
• Maron-Gutierrez T, Castiglione RC, Xisto DG, et al. Bone marrow-derived mononuclear cell therapy attenuates silica-induced lung fibrosis. Eur Respir J. 2011;37(5):1217–1225. DOI:10.1183/09031936.00205009
   PubMedGoogle Scholar
• Lopes-Pacheco M, Ventura TG, de Oliveira HD, et al. Infusion of bone marrow mononuclear cells reduces lung fibrosis but not inflammation in the late stages of murine silicosis. PLoS ONE. 2014;9(10):e109982. DOI:10.1371/journal.pone.0109982
   PubMedGoogle Scholar
• de Oliveira HD, de Melo EBB, Silva JD, et al. Therapeutic effects of bone marrow-derived mononuclear cells from healthy or silicotic donors on recipient silicosis mice. Stem Cell Res Ther. 2017;8(1):259. DOI:10.1186/s13287-017-0699-7
   PubMedGoogle Scholar
• Lopes-Pacheco M, Xisto DG, Ornellas FM, et al. Repeated administration of bone marrow-derived cells prevents disease progression in experimental silicosis. Cell Physiol Biochem. 2013;32(6):1681–1694. DOI:10.1159/000356603
   PubMedGoogle Scholar
• Li X, An G, Wang Y, et al. Targeted migration of bone marrow mesenchymal stem cells inhibits silica-induced pulmonary fibrosis in rats. Stem Cell Res Ther. 2018;9(1):335. DOI:10.1186/s13287-018-1083-y
   PubMedGoogle Scholar
• Silva LHA, Silva MC, Vieira JB, et al. Magnetic targeting increases mesenchymal stromal cell retention in lungs and enhances beneficial effects on pulmonary damage in experimental silicosis. Stem Cells Transl Med. 2020;9(10):1244–1256. DOI:10.1002/sctm.20-0004
   PubMed Web of Science ®Google Scholar
• Bandeira E, Oliveira H, Silva JD, et al. Therapeutic effects of adipose-tissue-derived mesenchymal stromal cells and their extracellular vesicles in experimental silicosis. Respir Res. 2018;19(1):104. DOI:10.1186/s12931-018-0802-3
   PubMedGoogle Scholar
• Choi M, Ban T, Rhim T. Therapeutic use of stem cell transplantation for cell replacement or cytoprotective effect of microvesicle released from mesenchymal stem cell. Mol Cells. 2014;37(2):133–139.
   PubMed Web of Science ®Google Scholar
• Aguiar FS, Melo AS, Araujo AMS, et al. Bone marrow-derived mononuclear cell therapy in a patient with severe asthma: a case report. Am J Respir Crit Care Med. 2017;195:A5320.
   Web of Science ®Google Scholar
• Ribeiro-Paes B, Greco OT, Greco OT, et al. Unicentric study of cell therapy in chronic obstructive pulmonary disease/pulmonary emphysema. Int J Chron Obstruct Pulmon Dis. 2011;6:63–71.
   PubMed Web of Science ®Google Scholar
• Stessuk T, Ruiz MA, Greco OT, et al. Phase I clinical trial of cell therapy in patients with advanced chronic obstructive pulmonary disease: follow-up of up to 3 years. Rev Bras Hematol E Hemoter. 2013;35(5):352–357. DOI:10.5581/1516-8484.20130113
   PubMedGoogle Scholar
• Weiss DJ, Casaburi R, Flannery R, et al. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest. 2013;143(6):1590–1598. DOI:10.1378/chest.12-2094.
   PubMed Web of Science ®Google Scholar
• Stolk J, Broekman W, Mauad T, et al. A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema. QJM. 2016;109(5):331–336. DOI:10.1093/qjmed/hcw001
   PubMed Web of Science ®Google Scholar
• de Oliveira HG, Cruz FF, Antunes MA, et al. Combined bone marrow-derived mesenchymal stromal cell therapy and one-way endobronchial valve placement in patients with pulmonary emphysema: a phase I clinical trial. Stem Cells Transl Med. 2017;6(3):962–969. DOI:10.1002/sctm.16-0315.
   PubMed Web of Science ®Google Scholar
• Chambers DC, Enever D, Ilic N, et al. A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis: safety of MSC therapy for IPF. Respirology. 2014;19(7):1013–1018. DOI:10.1111/resp.12343
   PubMed Web of Science ®Google Scholar
• Glassberg MK, Minkiewicz J, Toonkel RL, et al. Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER). Chest. 2017;151(5):971–981. DOI:10.1016/j.chest.2016.10.061.
   PubMed Web of Science ®Google Scholar
• Zhang C, Yin X, Zhang J, et al. Clinical observation of umbilical cord mesenchymal stem cell treatment of severe idiopathic pulmonary fibrosis: a case report. Exp Ther Med. 2017;13(5):1922–1926. DOI:10.3892/etm.2017.4222
   PubMedGoogle Scholar
• Campo A, González-Ruiz JM, Andreu E, et al. Endobronchial autologous bone marrow–mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial. ERJ Open Res. 2021;7(2):00773–02020. DOI:10.1183/23120541.00773-2020
   PubMedGoogle Scholar
• Averyanov A, Koroleva I, Konoplyannikov M, et al. First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline. Stem Cells Transl Med. 2020;9(1):6–16. DOI:10.1002/sctm.19-0037
   PubMed Web of Science ®Google Scholar
• Morales MM, Souza SAL, Loivos LP, et al. Pilot safety study of intrabronchial instillation of bone marrow-derived mononuclear cells in patients with silicosis. BMC Pulm Med. 2015;15(1):66. DOI:10.1186/s12890-015-0061-8.
   PubMedGoogle Scholar
• Naji A, Eitoku M, Favier B, et al. Biological functions of mesenchymal stem cells and clinical implications. Cell Mol Life Sci. 2019;76(17):3323–3348. DOI:10.1007/s00018-019-03125-1
   PubMed Web of Science ®Google Scholar